2020 American Transplant Congress » Poster Session B: Kidney Chronic Antibody Mediated Rejection

3:30pm-4:00pm

Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection – Molecular Rebound Phenomena Under IL-6 Blockade?

A. Borski¹, S. Haindl², M. Duerr³, K. Budde³, S. Schranz¹, F. A. Eskandary², K. Doberer², P. F. Halloran⁴, E. Chong⁵, B. Jilma¹, G. A. Böhmig², M. Wahrmann²

3:30pm-4:00pm

Are Molecular Diagnoses of Antibody Mediated Rejection (ABMR) Reliable in the Setting of Antibody-Antigen Complex Mediated Tissue Injury Unrelated to Alloimmunity?

P. Randhawa¹, Y. Huang¹, G. Tseng², K. Xiao³

3:30pm-4:00pm

CD38 Antibody Daratumumab for the Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection

K. Doberer¹, J. Kläger², G. A. Gualdoni¹, K. Mayer¹, F. Eskandary¹, H. Agis³, T. Reiter¹, R. Reindl-Schwaighofer¹, M. Wahrmann¹, G. Cohen¹, H. Haslacher⁴, G. Bond¹, I. Simonitsch-Klupp⁵, I. Farkash⁶, P. Halloran⁷, G. A. Böhmig¹

3:30pm-4:00pm

Calcineurin Inhibitor Withdrawal is the Significant Risk Factor for De Novo DSA Production in Living Donor Kidney Transplantation

T. Hiramitsu¹, T. Tomosugi¹, K. Futamura¹, M. Okada¹, N. Goto¹, S. Narumi¹, K. Uchida², Y. Watarai¹

3:30pm-4:00pm

Clazakizumab (Anti-IL-6 Monoclonal) as an Agent to Reduce Donor Specific Hla Antibodies (DSA) and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation (NCT03380377)

S. C. Jordan, N. Ammerman, M. Toyoda, S. Ge, E. Huang, A. Peng, S. Sethi, R. Najjar, E. Ortiz, M. Chu, A. De Guzman, I. Kim, K. Lim, J. Choi, A. Vo

3:30pm-4:00pm

Clinical Significance of Late Antibody-Mediated Rejection without Donor Specific Anti-hLA Antibodies

J. Lee¹, E. Kim¹, S. Yang¹, S. Kim¹, B. Lim², H. Choi³, B. Kim⁴, B. Kim⁴, M. Ju⁵, M. Kim¹, S. Kim¹, Y. Kim¹, K. Huh¹

3:30pm-4:00pm

Early Impact of Interleukin-6 Blockade on the Distribution of Peripheral Blood Immune Cell Subpopulations – 3-Month Results of a Phase 2 Trial Evaluating Clazakizumab in Late Antibody-Mediated Rejection

K. A. Doberer¹, G. A. Boehmig¹, M. Streitz², S. Schlickeiser², F. Bauernfeind¹, A. Spittler³, B. Jilma⁴, F. Eskandary¹, E. Chong⁵, S. Schranz⁴, K. Budde⁶, M. Dürr⁶

3:30pm-4:00pm

Mid-Term Outcomes after Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?

M. Okada¹, T. Tomosugi¹, T. Hiramitsu¹, S. Narumi¹, Y. Watarai¹, A. Kanda¹, K. Futamura¹, N. Goto¹, A. Takeda²

3:30pm-4:00pm

Multifaceted Roles of Follicular T Cell Subsets in Controlling Antibody Mediated Rejection

M. T. Mohammed

3:30pm-4:00pm

Post-Transplant Collagen I and Collagen III Antibodies and Antibody-Mediated Rejection in Kidney Transplantation Recipients

S. Park¹, S. Yang², J. Kim², Y. Kim², Y. Kim², J. Ha², K. Moon², E. Song², H. Lee²

3:30pm-4:00pm

Reduced Dose of Mycophenolate Mofetil as Well as Preformed DSA Are Risk Factors Associated with the Development of Chronic Active Antibody Mediated Rejection after Kidney Transplantation: A Retrospective Case Control Study

K. Shinoda¹, H. Oguchi¹, K. Nishikawa¹, T. Yonekura¹, M. Muramatsu¹, T. Kawamura¹, Y. Hamasaki¹, T. Mikami², K. Sakai¹, S. Shishido¹

3:30pm-4:00pm

The Evolution and Impact of ABMR Histology and Transplant Glomerulopathy in the Presence or Absence of HLA-DSA

M. Coemans¹, A. Senev¹, G. Verbeke², M. Emonds¹, M. Naesens¹

3:30pm-4:00pm

Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients is Associated with Increased Risk of Urinary Tract Infections and Pneumonia

E. Joachim, S. Parajuli, K. Swanson, F. Aziz, N. Garg, M. Mohamed, D. Mandelbrot, A. Djamali

3:30pm-4:00pm

Validation of Prognostic Index for Allograft Outcome in Kidney Transplant Recipients with Transplant Glomerulopathy

M. Talwar¹, V. Balaraman¹, A. Bhalla¹, O. Cseprekal², M. Yazawa¹, P. S. Podila³, A. Azhar¹, L. N. Cossey⁴, J. D. Eason¹, M. Z. Molnar¹